NCT05598645

Brief Summary

This study aims to compare the efficacy and safety of both types of lasers, Holmium MOSES and TFL, in management of kidney stones requiring treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
174

participants targeted

Target at P75+ for not_applicable

Timeline
4mo left

Started Aug 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Aug 2022Sep 2026

Study Start

First participant enrolled

August 16, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 25, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 28, 2022

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

August 7, 2024

Status Verified

August 1, 2024

Enrollment Period

3.8 years

First QC Date

October 25, 2022

Last Update Submit

August 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Procedural Time

    Measured in number of minutes from the insertion of the ureteroscope to the removal of the ureteroscope.

    Intraoperative

Secondary Outcomes (7)

  • Stone Free Rate (SFR)

    4 and 12 weeks post-op

  • Total operative time

    Intraoperative

  • Lasing time

    Intraoperative

  • Total energy used

    Intraoperative

  • Laser efficiency

    Intraoperative

  • +2 more secondary outcomes

Study Arms (2)

Thulium Fibre Laser (TFL)

EXPERIMENTAL

Patients randomized to this arm will undergo treatment using the TFL.

Device: Thulium Fibre Laser

MOSES Holmium Laser

EXPERIMENTAL

Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.

Device: MOSES Holmium Laser

Interventions

Participants will undergo treatment using the TFL

Thulium Fibre Laser (TFL)

Participants will undergo treatment using the MOSES Holmium laser.

MOSES Holmium Laser

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age and over at the time of enrollment.
  • Patients referred with single kidney stones of 10-20 mm in its largest diameter, or multiple stones involving a single calyx.
  • Written informed consent to participate in the study
  • Ability to comply with the requirements of the study procedures

You may not qualify if:

  • Patients with ipsilateral distal ureteral stones or stricture.
  • Stone size \> 20 mm or multiple kidney stones in different calyces.
  • Previous shock wave lithotripsy (SWL) treatment for the same stone.
  • Participants with active urinary tract infection until appropriately treated
  • Uncorrected coagulopathy (anticoagulants or blood thinners which cannot be withheld before surgery).
  • Pregnancy.
  • Participants with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study.
  • Participants who are uncooperative or cannot follow instructions.
  • Participants who lack the capacity, or cannot speak English, in order to provide free and informed written consent.
  • Patients with solitary kidney.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thunder Bay Regional Health Sciences Centre

Thunder Bay, Ontario, P7B 6V4, Canada

RECRUITING

MeSH Terms

Conditions

Kidney Calculi

Condition Hierarchy (Ancestors)

NephrolithiasisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrolithiasisUrinary CalculiMale Urogenital DiseasesCalculiPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Hazem Elmansy, MD

    Urologist

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shalyn Littlefield, MSc

CONTACT

Hazem Elmansy, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 25, 2022

First Posted

October 28, 2022

Study Start

August 16, 2022

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

August 7, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations